ABN Newswire http://www.abnnewswire.net Wed, 30 May 2012 03:53:16 newsroom@abnnewswire.net newsroom@abnnewswire.net 60 <![CDATA[ Pioneers Holding Co.(CAI:PIOH) übernimmt Beltone Financial ]]> de61212 Y http://www.abnnewswire.net/press/de/61212/ Thu, 12 Nov 2009 14:00:07 GMT Das Board von Pioneers Holding Co.(CAI:PIOH)vereinbart, Beltone Financial Company durch die Erhöhung des Grundkapitals der Gesellschaft und Aktientausch mit den Aktionären der Beltone Financial zu austauschen.

Pioneers Holding Co. (CAI:PIOH)wird 100 Millionen neue Aktien ausgeben, mit dem gesamten Wert der Beltone Financial, und geben Beltone ein 17%-Beteiligung an dem fusionierten Unternehmen.

Dieser Schritt wird das größte Unternehmen in der Investment Banking-Bereich in der MENA-Region einrichten, profitiert von der starken Aspekte der beiden Parteien.
Der Zusammenschluss ist mit der Prüfung der Due-Diligence-bedingt und die notwendigen Genehmigungen.

Aladdin Saba, CEO von Beltone Financial, sagte, dass der Zusammenschluss der größten Investment-Banking-Einheit in der Region des Nahen Ostens sein wird.

Beltone besitzt auch ein großes Kundennetz die Individuen von hohem Nettowert und starke Verhältnisse mit Führeninstitutionen beide regional und global, fördernd sein institutionelles Maklergeschäftgeschäft.

Zusätzlich, Beltone hat starker Forschung bei zahlend Investition und assest Leitung Betriebe, das letzte mit Vermögenswerten unter Leitung von ungefähr 26 Milliarden Ägypter Pfund.

Dr. Mansour Al Gammal, Pioneers 'Vice Chairman, fügte hinzu, dass sein Unternehmen die größte Retail Brokerage Kundenstamm in Ägypten hat, von rund 90.000 Investoren, über ein Netz von 30 Filialen in Ägypten, Saudi-Arabien und Syrien.

Omar Mostafa 
TEL: +61-2-9247-4344 
EMAIL: omar.mostafa@abnnewswire.net

]]> newsroom@abnnewswire.net <![CDATA[ OncoMethylome Sciences (EBR:ONCOB) OncoMethylome Appoints New Board Director And New COO ]]> de61144 Y http://www.abnnewswire.net/press/de/61144/ Sat, 24 Jan 2009 04:01:00 GMT
Mr. Gerard Vaillant, will join the Board of Directors of OncoMethylome effective February 19, 2009. Mr. Vaillant has extensive experience in the health care and molecular diagnostics industry. He has served as Group Chairman of Johnson&Johnson (J&J) and Chairman of Ortho-Clinical Diagnostics Inc., Veridex Inc., and Therakos Inc. He has personally managed the development, manufacturing, and commercialization of numerous healthcare products throughout the world. He currently is a Board member of Luminex Corporation (US), Tecan AG (CH), IntegraGen SA (F), Vivacta Ltd. (UK), and Sensors for Medicine and Science, Inc. (US).

Dr. Christian Schneider, a leading venture capital investor in Europe has been a Board member or Board representative at OncoMethylome since its creation in 2003. He has resigned his position as a director at OncoMethylome in order to be able to devote more time to a new European life sciences venture capital fund and to earlier-stage healthcare companies.

Mr. Gert-Jan Renardel de Lavalette will become the COO of OncoMethylome Sciences starting on February 2, 2009. In this newly created management position at OncoMethylome, Mr. Renardel will focus on the development and commercialization of the numerous products of OncoMethylome. Mr. Renardel brings over 20 years of experience in the diagnostics and pharmaceutical industry from his previous management positions at Schering-Plough and Akzo Nobel.

Dr. Robert Timmins, Chairman of the Board of OncoMethylome Sciences stated the following, "We thank Dr. Schneider for his excellent insight and support in building OncoMethylome over the last 6 years. We also strongly welcome Mr. Vaillant as a new director and Mr. Renardel as COO of our company. With the increasing number of OncoMethylome's products reaching the market, Mr. Vaillant's and Mr. Renardels' extensive experience in managing and commercializing diagnostic products throughout the world for companies such as J&J and Organon will definitely be a tremendous advantage to OncoMethylome.

To download this press release as a PDF, click here: Press Release

About OncoMethylome Sciences OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.

OncoMethylome boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC (a Johnson & Johnson company), LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, Millipore Corporation's BioScience Division, EXACT Sciences Corp., Merck KGaA, and Qiagen, OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).

Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).
For more information please contact: Philip Devine Tel. +32 479 505 885 ir@oncomethylome.com www.oncomethylome.com

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.


LINK: http://hugin.info/137314/R/1284599/287834.pdf

OncoMethylome Sciences

http://www.oncomethylome.com

ISIN: BE0003844611

Stock Identifier: XBRU.ONCOA ]]> newsroom@abnnewswire.net <![CDATA[ Directors' Dealings: Carl Zeiss Meditec AG (FRA:AFX) : Director's Dealings Announcement According To §15a WpHG (the German Securities Trading Act) ]]> de61145 Y http://www.abnnewswire.net/press/de/61145/ Sat, 24 Jan 2009 04:01:00 GMT


-------------------------------------------------------------------------------- Details of the person subject to the disclosure requirement --------------------------------------------------------------------------------

Michael Dr. Kaschke

Person with executive functions - Member of a managing body

President and CEO of Carl Zeiss Meditec

-------------------------------------------------------------------------------- Designation of the financial instrument --------------------------------------------------------------------------------

ISIN..........................: DE000CB23DV1 Designation...................: Discount Warrants



-------------------------------------------------------------------------------- Additional details on derivatives --------------------------------------------------------------------------------

ISIN underlying instrument....: DE0005313704 Strike price..................: Price multiplier..............: Expiration date...............: 14.05.2009



-------------------------------------------------------------------------------- Details of the transaction --------------------------------------------------------------------------------

Type of transaction...........: Buy Date..........................: 14.01.2009 Place (stock exchange)........: Stuttgart Price.........................: 5,75 Currency......................: EUR Quantity......................: 3.500 Business volume...............: 20125



Carl Zeiss Meditec AG Goeschwitzer Strasse 51-52 Jena D-07745 Germany

Index: - Prime All Share - TECH All Share - TecDAX Listed: - Freiverkehr in Bayerische Börse München - Freiverkehr in Börse Berlin - Freiverkehr in Börse Düsseldorf - Freiverkehr in Börse Stuttgart - Geregelter Markt in Frankfurter Wertpapierbörse - Prime Standard in Frankfurter Wertpapierbörse - Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg - Freiverkehr in Niedersächsische Börse zu Hannover

--- End of Message ---

Carl Zeiss Meditec AG Goeschwitzer Strasse 51-52 Jena Germany

WKN: 531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share, TecDAX; Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Geregelter Markt in Frankfurter Wertpapierbörse;

Carl Zeiss Meditec AG

www.meditec.zeiss.com

ISIN: DE0005313704

Stock Identifier: XFRA.AFX ]]> newsroom@abnnewswire.net <![CDATA[ Solteq Oyj (HEL:STQ1V) SHARE REPURCHASE 23.1.2009 ]]> de61143 Y http://www.abnnewswire.net/press/de/61143/ Sat, 24 Jan 2009 03:39:00 GMT




SHARE REPURCHASE 23.1.2009



In the Helsinki Stock Exchange



Trade date 23.1.2009

Bourse trade BUY

Share STQ1V

Amount 1.400 shares

Total cost 1.528,00 EUR

Average price/ share 1,0914 EUR

Highest price/ share 1,12 EUR

Lowest price/ share 1,02 EUR





Solteq Plc now holds a total of 215.795 shares

including the shares repurchased on 23.1.2009.





On behalf of Solteq Plc



NORDEA BANK FINLAND PLC



Petri Simberg Julius Summanen

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Solteq Oyj

http://www.solteq.com

ISIN: FI0009007991

Stock Identifier: XHEL.STQ1V ]]> newsroom@abnnewswire.net <![CDATA[ Actelion Pharmaceuticals Ltd (VTX:ATLN) Actelion To Host Actelion Day On 19 February 2009 ]]> de61142 Y http://www.abnnewswire.net/press/de/61142/ Sat, 24 Jan 2009 03:37:00 GMT


Dear member of the investment community

Actelion Ltd will announce the financial full year 2008 results on Thursday, 19 February 2009, at 07.00 CET / 01.00 EST / 06.00 GMT.

The same day, the company hosts Actelion Day 2009. This event will be a combination of Actelion's annual Media and Analyst Conference (M&A Day) and its Research and Development Day (R&D Day).

The event will be available via webcast, however, questions will be restricted to audience members only.

For those of you who have not received a personalized invitation as a buy- or sell-side analyst and wishing to attend the event in person, we kindly ask to send an e-mail to investor.relations@actelion.com. Please note that space is limited.

Actelion will host an Investor Conference Call / Webcast as follows:

Date/Time:

19 February 2009 12.30 hrs - 16.30 hrs Basel (CEST) 11.30 hrs - 15.30 hrs U.K. (BST) 06.30 a.m. - 10.30 a.m. U.S. (EDT)

Conference Call Connect #: Dial-in participants should start calling the number below 10-15 minutes before the Conference is due to start.

Dial: Europe: +41 44 580 64 03 U.K.: +44 207 153 91 54 U.S.: +1 866 928 60 44

Participant's mode: Listen-Only. Questions will be restricted to audience members only.

Webcast Access: Webcast participants should visit the Actelion website for further details http://www.actelion.com/ 10-15 minutes before the conference is due to start.

Participant's mode: Listen-Only. Questions will be restricted to audience members only.

Webcast Replay: The archived Investor Webcast will be available for replay through http://www.actelion.com/ approximately 60 minutes after the call has ended.

For further information please contact: Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil Roland Haefeli Vice President, Head of Investor Relations & Public Affairs +41 61 565 62 62 +1 650 624 69 36 http://www.actelion.com

--- End of Message ---

Actelion Pharmaceuticals Ltd Gewerbestrasse 16 Allschwil Switzerland

WKN: 936767; ISIN: CH0010532478; Index: SBIOM, SLIFE, SMCI, SMIEXP, SMIM, SPI, SPIEX; Listed: Main Market in SIX Swiss Exchange;



LINK: http://hugin.info/131801/R/1284612/287837.pdf

Actelion Pharmaceuticals Ltd

http://www.actelion.com

ISIN: CH0010532478

Stock Identifier: XSWX.ATLN

US: OTC:ALIOF ]]> newsroom@abnnewswire.net <![CDATA[ Ability Drilling AS (OSL:ADRL) Ability Drilling And Geoenergie Bayern Cancel Agreement ]]> de61141 Y http://www.abnnewswire.net/press/de/61141/ Sat, 24 Jan 2009 02:47:00 GMT
Ability Drilling and Geoenergie Bayern cancel agreement

Ability Drilling and Geoenergie Bayern have agreed to terminate its agreement. The agreement included a drilling contract for land Rig no. 2, originally scheduled to start operations in Germany in Q4 2008.

According to CEO Hans Petter Eikeland there are several reasons for the termination of the agreement: "Delivery delays triggered the customer's decision regarding land rig no. 2, but the overall picture with lower energy prices worldwide, which is related to the current situation in the world economy, is also an important factor. We could not agree on the terms for a future partnership and decided to terminate the agreement."

Mr. Eikeland still believes geothermal drilling is an interesting market for Ability Drilling, but expects that it will take some time before the availability of projects improves. "Our rigs are very well suited for this type of projects, and we are in contact with several possible future customers. However, we believe that both credit issues and energy prices will slow down the market for a while."

The CEO confirms that Ability Drilling is negotiating new contracts for the rigs available for the market. "Negotiations are progressing well for all rigs, but the termination of contracts with Porosity and Geoenergie negatively impacts our business in the current quarter as we cannot employ the rigs over the night. Consequently, we have reduced manning and cost to adapt to the current situation while we are finalising new contracts. We expect this to be solved in Q1."

For further information, please contact:

CEO Hans Petter Eikeland, phone +47 56 32 43 43, or +47 93 20 81 77 CFO Kenneth Tunes, tlf. 56 32 43 43, eller 91 54 49 01

About Ability Drilling ASA: Ability Drilling aims to become the preferred operator and provider of Rack & Pinion (R&P) rigs in its defined core markets, by combining fourth generation drilling technology with outstanding drilling experience from offshore North Sea exploration and production activities.

The Company currently targets onshore oil operations in the MENA (Middle East North Africa) market, the geothermal market in Europe, as well as the market for drilling of LNG reservoirs. Both the land rig market in MENA and the geothermal segment in Europe are markets with strong growth and significant potential, while the market for drilling of LNG reservoirs is an emerging growth segment. Ability Drilling targets extension of the geographical footprint within all current focus areas.

Ability Drilling has so far ordered 11 rigs, of which 9 land rigs, one 150 T workover rig and one 150 T Ultra Light Drilling Rig. In addition, the company has options with construction partner TTS Sense for 33 additional land rigs and 40 additional workover rigs.

Ability Drilling is listed on Oslo Axess, with ticker ADRL.

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Ability Drilling AS

http://www.ability-drilling.com/

ISIN: NO0010333024
Stock Identifier: OSE.ADRL ]]> newsroom@abnnewswire.net <![CDATA[ Jelmoli (VTX:JEL) Shareholders Approve The Strategic Plan ]]> de61140 Y http://www.abnnewswire.net/press/de/61140/ Sat, 24 Jan 2009 02:35:00 GMT


At an extraordinary meeting held today, shareholders in Jemoli Holding Ltd ("Jelmoli") approved the Board's proposals for the strategic future of the Company. These proposals promulgated (i) the creation of two independent entities, i.e. an real estate company (Jelmoli) and an investment company (Athris), by way of a tax neutral distribution of Athris shares to Jelmoli shareholders, (ii) the removal of the dual class share structure in the proposed Real Estate Company (Jelmoli), (iii) a premium to Pelham Investments S.A. ("Pelham") in form of subscription rights for ceding control in the Real Estate Company (Jelmoli), and (iv) a cash exit option for shareholders in the investment company (Athris) by way of buy-back program of Athris.

182 shareholders attended today's Extraordinary General Meeting. They represented 68.0 percent of the company's share capital and 83.9 percent of votes. All four agenda items, (i) distribution of Athris shares, (ii) share unification at Jelmoli, (iii) authorized capital for the distribution of the reverse premium to Pelham and (iv) consultative vote on the buyback program at Athris have been approved in each case with more than 95% of the votes. Agenda item (iii), which required also capital majority, was approved with more than 92% of the share capital present.

The completion of the Strategic Plan, including (i) distribution and start of trading of the Athris shares on SIX Swiss Exchange, (ii) start of trading of the single class of Jelmoli shares (Einheitsaktie) on SIX Swiss Exchange, and (iii) launch of the Athris buy-back program, is expected to occur in March 2009 once all SIX and regulatory approvals have been obtained and preparations for the technical implementation have been completed.

"Today is an important day for Jelmoli and its shareholders. Much has been achieved in recent months to create a strong platform for the future success of both Jelmoli and Athris against a backdrop of the most difficult market conditions experienced in a generation. I am delighted that shareholders have overwhelmingly agreed with our proposals and that the Strategic Plan can now be implemented", said Christopher Chambers, Chairman of the Board of Directors.

Background Information

The Strategic Plan With today's resolutions Jelmoli shareholders have approved the Strategic Plan which comprises the following key elements:

* Separation of Jelmoli into two separately listed companies, a Real Estate Company (Jelmoli) and an Investment Company (Athris). The creation of the two stand-alone businesses will take the form of a tax-neutral distribution of the shares in the Investment Company to Jelmoli shareholders. * In the Real Estate Company, which will continue to operate under the name Jelmoli Holding Ltd, the share structure will be unified and the current controlling shareholder Pelham Investments S.A. ("Pelham") will give up control. The Real Estate Company's share capital will comprise only one registered share class once trading in its stock commences. Currently existing bearer shares will be converted into registered shares at a ratio of 1:5. In Athris, the dual class shareholder structure will be maintained and Pelham will continue to be the controlling shareholder. * As compensation for ceding control in the Real Estate Company, Pelham will receive a reverse premium of 50,000 new bearer share equivalents at nominal value, which represents a premium of approximately 18% on Pelham's stake in the Real Estate Company. The reverse premium offered to Pelham will translate into 250,000 registered shares which will be issued to Pelham at book value with the exclusion of subscription rights of other shareholders. The shareholding of Pelham in the Real Estate Company will thereby increase from 25.2% to 29.8% of shares issued, while at the same time voting rights will decrease from 52.9% to 29.8%. * In the Investment Company, which will operate under the name of Athris, Pelham will retain control. Shareholders will have the option to either stay fully invested in the Company or to sell a significant part of their position. As a result, Athris will offer a cash exit option for shareholders in the Investment Company through a share buyback program. Shareholders will receive tradable put options which will allow them to put back shares to the Investment Company at a discount of 15% to book equity, up to a total buy-back amount of CHF 400 million. * The shares of Jelmoli and Athris as well as the tradable put options are expected to commence trading in March 2009.

The Real Estate Company (Jelmoli) The Real Estate Company will be the second largest public real estate company in Switzerland with a property market value of approximately CHF 3.2 billion and a book equity value of approximately CHF 1.6 billion as per 30.6.2008. Jelmoli is uniquely positioned through its exclusive focus on the Swiss market, its outstanding real estate portfolio in particular in Zurich and Geneva, low vacancy rates and long maturity of rental contracts. It is further the only major Swiss real estate company where the majority of its rental income is derived from retail tenants. Jelmoli has a conservative capital structure with a loan-to-value ratio of 40% as of 30.6.2008. The House of Brands and Bonus Card will remain with the Real Estate Company and will provide significant value upside through the further optimization of these retail operations. The completion of key development projects (such as the shopping center in Stuecki in Basle) in the Tivona portfolio will further positively impact the real estate value of the group going forward.

The Investment Company (Athris) As an investment company, Athris will hold cash and financial receivables, the Seiler Hotels, the less conservative real estate participations in Russia and Algeria as well as the other retail trade businesses that do not belong to Jelmoli's core business, such as Molino, Beach Mountain and Fundgrube. The equity of the Investment Company resulting from the pro forma balance sheet as at 30 June 2008 (before the share buyback program) amounts to approximately CHF 1.1 billion. The current market environment offers attractive opportunities for companies with cash to invest. With the goal to further increase the equity book value in the future, Athris shall not be subject to rigid assets allocation, but may, within the scope of its investment guidelines, pursue investment opportunities which seem to be most advantageous. Athris has the aim to adopt a total income-return oriented investment strategy with a transparent and tax efficient structure and to enable its shareholders to participate in its success by an appreciation of the shares.

Tivona Jelmoli announced today a settlement of the outstanding litigation regarding Tivona and will acquire subject to the fulfillment of certain closing conditions the 55.5% it does not already own from the Tivona shareholders. The transaction is expected to close in the first quarter 2009. Tivona is a Swiss real estate company focused on commercial retail properties such as on large shopping centers and specialized discount stores.

For further details see the information brochure to shareholders regarding the extraordinary shareholders meeting of Jelmoli Holding Ltd of 23 January 2009 (www.jelmoliholding.ch).

Contact person

Media: Dr. Jörg Neef, Hirzel. Neef. Schmid. Konsulenten +41 79 405 56 32, eMail: joerg.neef@konsulenten.ch Internet: www.jelmoliholding.ch / www.huginonline.ch/JEL WAP mobile: wap.huginonline.com (Press Releases Jelmoli) E-mail: info@jelmoliholding.ch

This media information contains forward looking statements which express intentions, estimates, expectations and forecasts relating to future financial, operational and other developments and results. Such statements and the underlying assumptions are subject to a variety of risks, uncertainties and other factors which could mean that the actual developments may significantly differ there from. Shareholder should also note that the transaction may fail, in full or in part, or may be delayed, for example if resolutions are challenged or if necessary approvals for the respective listing documents were not granted. In view of these uncertainties, readers of this media information are cautioned not to place undue reliance on such forward looking statements.

This document does not contain or constitute an offer to sell or a solicitation of any offer to buy securities in the United States or in any other jurisdiction in which such offer or solicitation is not authorized or to any person to whom it is unlawful to make an offer or solicitation. The securities have not been and will not be registered under the United States securities laws and may not be offered or sold in the United States.

--- End of Message ---

Jelmoli -----------------------------------------
Jelmoli über WAP:
wap.huginonline.com
-----------------------------------------
St. Annagasse 18 Zürich

WKN: 851225; ISIN: CH0000668464; Index: SMCI, SPI, SPIEX; Listed: Main Market in SIX Swiss Exchange;



LINK: http://hugin.info/100248/R/1284643/287851.pdf

Jelmoli

http://www.jelmoli-holding.ch/

ISIN: CH0000668464

Stock Identifier: XSWX.JEL

US: JMLIF.PK ]]> newsroom@abnnewswire.net <![CDATA[ Biotec Pharmacon ASA (OSL:BIOTEC) MARKET MAKER AGREEMENT ]]> de61139 Y http://www.abnnewswire.net/press/de/61139/ Sat, 24 Jan 2009 02:33:00 GMT
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Biotec Pharmacon ASA

http://www.biotec.no

ISIN: NO0010014632

Stock Identifier: XOSL.BIOTEC ]]> newsroom@abnnewswire.net <![CDATA[ Telenor (OSL:TEL) New Timeframe For Closing Of India Transaction ]]> de61138 Y http://www.abnnewswire.net/press/de/61138/ Sat, 24 Jan 2009 01:37:00 GMT
On 23 December 2008, Telenor announced that it expected to close the Unitech Wireless transaction during January 2009. Closing is subject to certain conditions being fulfilled, and Telenor now anticipates that closing of the transaction will take place during the first quarter of 2009.

Telenor remains confident that all conditions will be met within the indicated timeframe, including agreements for infrastructure sharing that will allow a swift and cost-efficient rollout.

For further information please contact: Esben Tuman, Information Manager, Telenor Asia, Phone: +66 859 184 111, Pål Kvalheim, Vice President Communication, Telenor ASA, Phone: +47 970 44 970

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Telenor

http://www.telenor.com

ISIN: NO0010063308

Stock Identifier: OSE.TEL

US: Nasdaq:TELN ]]> newsroom@abnnewswire.net <![CDATA[ Stolt-Nielsen S.A. (OSL:SNI) Presentation And Conference Call Fourth-Quarter and Full Year 2008 Results - Confirmation Of Venue ]]> de61137 Y http://www.abnnewswire.net/press/de/61137/ Sat, 24 Jan 2009 01:21:01 GMT
The presentation and call will take place at Shippingklubben, Haakon VII's gate 1, in Oslo, Norway.

Making the presentation and the call will be:

- Mr. Niels G. Stolt-Nielsen - Chief Executive Officer, Stolt-Nielsen S.A. - Mr. Jan Chr. Engelhardtsen - Chief Financial Officer, Stolt-Nielsen S.A.

For additional information please contact:

Jan Chr. Engelhardtsen Chief Financial Officer UK +44 (0) 20 7611 8972 j.engelhardtsen@stolt.com

Jens F. Grüner-Hegge V.P. Corporate Finance UK +44 (0) 20 7611 8985 j.gruner-hegge@stolt.com

About Stolt-Nielsen S.A. Stolt-Nielsen S.A. (the "Company") is one of the world's leading providers of transportation services for bulk liquid chemicals, edible oils, acids, and other specialty liquids. The Company, through the parcel tanker, tank container, terminal, rail and barge services of its wholly owned subsidiaries Stolt Tankers & Terminals and Stolt Tank Containers, provides integrated transportation solutions for its customers. Stolt Sea Farm, wholly owned by the Company, produces and markets high quality turbot, sole, sturgeon and caviar.

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Stolt-Nielsen S.A.

http://www.stolt-nielsen.com

ISIN: LU0081746793

Stock Identifier: XOSL.SNI

US: Nasdaq:SNSA ]]> newsroom@abnnewswire.net